Ariceum Therapeutics
Juergen Fleck is an accomplished professional in clinical operations and development, currently serving as the Head of Development Operations at Ariceum Therapeutics since June 2023. With extensive experience in leading clinical operations, Fleck previously held the position of Head Of Clinical Operations at Recordati Rare Diseases, focusing on global endocrinology projects from April 2020 to May 2023. Prior to that, Fleck was at Advanced Accelerator Applications as Director of Development Operations, overseeing global clinical trials in radioligand therapies for oncology. A substantial tenure at Novartis included roles such as Franchise Clinical Operations Head in Global Medical Affairs for oncology, demonstrating expertise in managing clinical trials. Earlier career milestones involved significant positions at Actelion Pharmaceuticals, Pfizer, and Ardeypharm, covering roles from Senior Clinical Scientist to Clinical Study Manager. Fleck’s academic credentials include a PhD in Biochemistry and Development Biology from Ruhr University Bochum and a Postdoctoral degree in Biochemistry and Ecology from The University of Georgia.
This person is not in any offices
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.